Compare e l f Beauty Inc (ELF) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Nuvalent Inc — how do they compare? e l f Beauty Inc trades at $76.39 (market cap $4.37B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is far larger — about 2.2× e l f Beauty Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals.
| ELF | NUVL | |
|---|---|---|
Market Cap | $4.37B | $9.81B |
Sector | Technology | Technology |
52-Week High | $146.67 | $123.96 |
52-Week Low | $49.57 | $72.16 |
Enterprise Value | $5.00B | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $76.11, up 5.34% with bullish technical signals and strong earnings beats. The stock shows robust revenue growth reaching $1.31B in 2025, though net margins remain thin at 1.61%. Recent analyst coverage is mixed with 46% buy ratings and consensus target of $74.42, slightly below current price. The company demonstrates solid operational cash flow of $133.84M and maintains a healthy balance sheet with $148.69M cash.
Outlook remains positive with continued double-digit sales growth targets, though elevated P/E ratio of 168.68 presents valuation concerns. Key risks include tariff exposure and core brand momentum challenges. Institutional sentiment leans bullish with recent price momentum supported by earnings outperformance and strategic expansion into skincare categories.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
